MARKET

UTHR

UTHR

United Therapeutics Corp.
NASDAQ
298.70
+4.10
+1.39%
After Hours: 298.70 0 0.00% 16:43 05/05 EDT
OPEN
294.52
PREV CLOSE
294.60
HIGH
299.45
LOW
292.02
VOLUME
295.74K
TURNOVER
--
52 WEEK HIGH
417.82
52 WEEK LOW
233.31
MARKET CAP
13.42B
P/E (TTM)
11.91
1D
5D
1M
3M
1Y
5Y
1D
Court dismisses United Therapeutics’ dispute against Liquidia
TipRanks · 2d ago
Liquidia rallies after judge rules against bid to delay Yutrepia
TipRanks · 3d ago
Liquidia price target raised at Scotiabank after ‘best case’ court ruling
TipRanks · 3d ago
Liquidia surges 15% as court clears way for Yutrepia launch
Seeking Alpha · 3d ago
United Therapeutics (UTHR) Receives a Buy from J.P. Morgan
TipRanks · 3d ago
United Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating
TipRanks · 3d ago
United Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 4d ago
United Therapeutics Price Target Cut to $350.00/Share From $355.00 by JP Morgan
Dow Jones · 4d ago
More
About UTHR
More
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Recently
Symbol
Price
%Change

Webull offers United Therapeutics Corp stock information, including NASDAQ: UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.